To put yesterday’s deal https://www.reuters.com/article/brief-bioasis-and-chiesi-group-announce-idUSFWN2E61EG in perspective, Bioasis’ (BTI) current market cap is only $16.85 CDN million so the milestone payments alone are more than 11 times that.
 
As well, BTI has already done significant research work on lysosomal storage disease already so I would expect, the road to milestone payments would be quicker than most people think.
 
  • additional potential milestone payments of up to US$138 million (~$190m CDN)
that's about $2 Cdn/share just in milestone payments 
 
  • and royalties on net sales from licensed products.
that's additional monies on top of the milestones
 
  • Chiesi Global Rare Diseases and Bioasis will host a joint webcast with details to be announced.
i'm very excited that the pharma is proud of this partnership so much so that they are
wanting to host a joint webcast for shareholders, their company followers, and the press.
 
A bit of background on Chiesi www.chiesi.com … a private company based in Parma, Italy, is an international research-focused healthcare group with 85 years of experience in the pharmaceutical industry and a global presence in 29 countries with 6000 employees and revenue of 1.8B Euro in 2018. Committed to being a leader in rare diseases and recently opened (Feb/2020) an office in Boston to focus on this https://www.globenewswire.com/news-release/2020/02/06/1980950/0/en/Chiesi-Group-Announces-Establishment-of-New-Global-Rare-Diseases-Division.html
 
In Bioasis’ latest MD&A document (also released yesterday), they state:
The Company is currently focused on securing financing via additional strategic partnership transactions for the Company’s xB3 drug delivery platform and has made significant progress in discussions with potential partners."
-and-
"The Company continues to pursue and progress into its strategic partnering discussions for the xB3 platform. We anticipate that additional partnerships may be transacted in 2020, with funds from upfront payments being invested in the pipeline".

so looks like this business development deal is just the beginning of more business development deals!
 
Beyond the financial component, a significant benefit of this of this partnership with a large European pharma is the validation for Bioasis’ xB3 platform beyond lysosomal storage disease.
I expect there will be a follow-up report from Edison Research (here’s the one from two weeks ago https://www.edisongroup.com/company/bioasis-technologies/2935/ ) discussing the importance of this deal and upping their share price target based on it.
I’m very excited for the future of this company!

Here's the PR from yesterday's news:

GUILFORD, Conn. & PARMA, Italy--()--BIOASIS TECHNOLOGIES INC. (“Bioasis”) (TSXV:BTI.V; OTCQB:BIOAF),a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including rare genetic diseases, brain cancers, neurodegenerative diseases and pain, and Chiesi Global Rare Diseases, a business unit of Chiesi Group, an international research-focused healthcare Group, today announced that they have entered into a worldwide, exclusive licensing agreement for the xB3 BBB platform technology in treatment of rare diseases with a focus on four undisclosed lysosomal storage disorders (“LSDs”).

Under the terms of the Research Collaboration and License Agreement (the “Agreement”), Chiesi Group will pay Bioasis an upfront payment of US$3 million. Bioasis may also be eligible to receive additional development, regulatory and commercial milestone payments of up to US$138 million, as well as additional royalties on net sales of licensed products, pending market approval. Chiesi Group will be responsible for all costs associated with research, development and commercialization of the four undisclosed LSD programs.

“With this collaboration, we are taking our commitment to bringing innovative therapies to rare disease patients, including those living with LSDs, to an entirely new level,” said Giacomo Chiesi, Head of Chiesi Global Rare Diseases, a business unit of Chiesi Group. “The unique delivery method of their xB3 platform has the potential to overcome a significant challenge in the treatment of many neurological disorders, which is the ability to cross the blood brain barrier. We look forward to working closely with the Bioasis team in advancing several new LSD clinical development programs using this technology platform.”

“We are very pleased to have entered into this agreement and excited to be working with Chiesi Group, a global company with a strong commitment to bringing innovative treatments to patients with LSDs,” said Deborah Rathjen, Ph.D., Bioasis’ Chair and Chief Executive Officer. “Neurological complications of LSDs remain largely untreatable when peripheral symptoms of disease respond to enzyme replacement therapy. Our xB3 BBB drug delivery platform has the potential to significantly advance the treatment of LSDs and the use of enzyme replacement therapy, solving one of the major unmet needs and improving the lives of patients.”

Chiesi Global Rare Diseases and Bioasis will host a joint webcast with details to be announced.

On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen, Ph.D., Chair & Chief Executive Officer

BTI-CRP

About Lysosomal Storage Disorders
Lysosomal storage disorders are inherited metabolic diseases that are characterized by an abnormal build-up of various toxic materials in the body's cells as a result of enzyme deficiencies. The build-up of toxic materials can affect different parts of the body, including the skeleton, brain, skin, heart and central nervous system. There are nearly 50 known LSDs. While there has been progress in clinical research to develop treatments in recent years, for most LSDs there are either no or limited treatment options available.

About Chiesi Global Rare Diseases
Chiesi Global Rare Diseases is a business unit of the Chiesi Group, established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders. The Global Rare Diseases unit works in collaboration with Chiesi Group to harness the full resources and capabilities of our global network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments available. The unit is also a dedicated partner with global leaders in patient advocacy, research and patient care.

About Chiesi Group
Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused healthcare group with 85 years of experience in the pharmaceutical industry and a global presence in 29 countries. Chiesi researches, develops, and markets innovative drugs in the respiratory therapeutics, specialist medicine, and rare disease areas. Its R&D organization is headquartered in Parma (Italy), and is integrated with R&D groups in France, the USA, the UK and Sweden to advance Chiesi's pre-clinical, clinical and registration programs. Chiesi employs nearly 6,000 people. Chiesi Group is a certified Benefit corporation. For more information, please visit www.chiesi.com.

About Bioasis
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 platform, a proprietary technology for the delivery of therapeutics across the BBB and the treatment of CNS disorders in areas of high unmet medical need. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. Bioasis’ internal pipeline programs are focused on treatments for certain brain cancers and rare diseases, including Gaucher’s Disease Type II, neurodegenerative diseases including Parkinson’s disease and Lewy Body Dementia and neuroinflammatory conditions including pain, epilepsy and Multiple Sclerosis. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the Company, please visit www.bioasis.us.